The lab of Gang Fang focuses on understanding the roles of bacterial epigenomes and complex gene splicing in neuropsychiatric disorders. They utilize advanced sequencing technologies to explore how bacteria adapt to their environments and how variations in gene splicing affect brain function related to disorders like schizophrenia and autism. Their research aims to identify new biomarkers and therapeutic targets that can improve treatment outcomes for these conditions.

Dr. Erin Savner Beck's lab focuses on understanding how multiple sclerosis affects the brain, specifically looking at cortical lesions that are often overlooked in standard imaging. The lab utilizes advanced MRI technology to study these lesions in newly diagnosed MS patients and investigates their relationship to disability progression. The findings aim to enhance our knowledge of MS and contribute to potential new treatments.

Dr. Brian D Brown's lab at the Icahn School of Medicine focuses on developing advanced RNA-based therapeutics, specifically modRNA (modified RNA), which can be used to improve vaccine responses and treat diseases. They are investigating how to control which types of cells produce proteins from modRNA, with the goal of enhancing the immune response to vaccines and potentially manipulating how the body tolerates certain proteins. This research is particularly relevant for developing more effective vaccines and therapies that target specific cells in the body.

Dr. Supinda Bunyavanich's lab focuses on understanding how the oral environment contributes to food allergies in young children. By studying saliva samples from a large cohort of children, they aim to identify how oral immunity, microbial communities, and metabolites change as food allergies develop. This research could lead to better prevention strategies and methods for detecting food allergy risks using simple saliva tests.

Dr. Masayuki Yazawa's lab focuses on developing new drugs to treat Timothy syndrome and other genetic heart conditions that cause dangerous heart rhythms. The research leverages innovative technologies and human-derived heart cells to create potential therapeutics. Through these efforts, the lab aims to better understand the molecular causes of these disorders and improve treatment options for affected patients.

Dr. Sarah E. Millar's research focuses on understanding the cellular mechanisms underlying diseases related to smell loss, aging-related eye health, and skin variation. Her lab investigates how COVID-19 can affect the brain via the sense of smell, explores treatments for Meibomian gland dysfunction which causes dry eye in elderly patients, and studies how skin responds differently to injuries and diseases. This research aims to find new therapies for these health issues.

Dr. Daniel Wacker's research lab explores cellular transporters in the brain that regulate the pH balance, crucial for maintaining proper neuronal function. The lab focuses on understanding the structure and function of specific bicarbonate transporters linked to neurological disorders, aiming to develop tools for drug discovery that could lead to new treatments. By combining various scientific techniques, the lab seeks to uncover the molecular mechanisms behind these transporters and their potential therapeutic applications.

Dr. Helen S. Mayberg's lab focuses on developing innovative treatments for patients with treatment-resistant depression using a technique called deep brain stimulation (DBS). By studying how the brain's electrical signals relate to patients' moods and behaviors, the lab aims to create a method that allows doctors to make more objective treatment decisions. This research could help improve the effectiveness and personalization of depression therapies, potentially benefiting many who struggle with this condition.

Dr. Lisa Miorin's lab focuses on understanding how specific genetic mutations affect the body's ability to fight off infections, particularly influenza. By studying a protein called ANKEF1 that helps move cilia in airway cells, the lab investigates how mutations can lead to severe complications like pneumonia and encephalitis. The research utilizes advanced technologies to explore the relationships between ciliary function, viral infections, and immune responses to identify potential new therapies for severe respiratory diseases.

Domenico Tortorella's lab at the Icahn School of Medicine focuses on developing new antiviral treatments for human cytomegalovirus (CMV), a common virus that can cause severe illness in newborns and immunocompromised patients. The research aims to identify and create compounds that can inhibit the early stages of CMV infection, potentially preventing its spread and reducing the associated health risks for vulnerable populations. This work is crucial as existing treatments often lead to drug resistance and severe side effects.

Dr. Robert J. Desnick's lab focuses on developing innovative treatments for rare genetic disorders, particularly Congenital Erythropoietic Porphyria (CEP). They are conducting clinical trials to test an oral medication, ciclopirox olamine, which aims to improve the enzyme activity deficient in patients with CEP. This research could potentially transform the lives of individuals with this challenging condition by alleviating symptoms and improving overall quality of life.

Dr. Robert S. Krauss's lab conducts innovative research focused on understanding complex developmental disorders and muscle regeneration. One area of study examines holoprosencephaly, a brain malformation influenced by genetic and environmental factors, particularly looking at how prenatal alcohol exposure affects embryonic development. The lab also investigates the mechanisms of muscle stem cell quiescence and activation, seeking to leverage insights into muscle regeneration for therapeutic applications.

Dr. Lakshmi A. Devi’s lab at the Icahn School of Medicine focuses on understanding how the body's natural opioid system interacts with ketamine, a medication that can treat depression and chronic pain. By studying how ketamine affects opioid receptors and their signaling pathways, the lab aims to uncover the mechanisms behind ketamine's rapid and lasting effects. This research has the potential to lead to better treatments for conditions like opioid use disorder and pain management.

Dr. Nicole Dubois' research lab focuses on understanding how the heart's basic building blocks, known as sarcomeres, are formed during development and how RNA-binding proteins like DDX3X play crucial roles in heart function and disease. By studying the mechanisms that lead to congenital heart defects and cardiomyopathies, the lab aims to uncover new therapeutic targets for heart diseases. They utilize cutting-edge technologies to explore both the structural and functional aspects of heart development.

Dr. Christopher F. Basler's lab at the Icahn School of Medicine investigates how the Ebola virus assembles and infects cells, focusing on a key protein called VP24. This protein not only helps package viral components but also interferes with the body's immune response. By understanding VP24's functions, the lab aims to uncover new strategies for preventing and treating Ebola infections.

Dr. Zahi A. Fayad's research lab focuses on improving outcomes in organ transplantation and understanding the effects of stress on cardiovascular disease. The lab investigates how innate immune responses, called trained immunity, can influence organ rejection and explores advanced imaging techniques for assessing heart conditions like cardiac sarcoidosis. Their goal is to create better therapies for transplant recipients and improve diagnostic methods for heart disease.

Dr. Matthew J. Evans' lab at the Icahn School of Medicine focuses on understanding how certain viruses, particularly flaviviruses like Zika and dengue, evade the human immune system. By studying the nonstructural protein 5 (NS5) of these viruses, the lab aims to reveal mechanisms of viral replication and immune suppression. This knowledge is crucial for developing new antiviral treatments and vaccines.

Dr. Daniel Michael Jordan's lab focuses on improving our understanding of genetic diseases and predicting disease risks for individuals with specific genetic markers. By using advanced techniques in deep learning, the lab analyzes large datasets from electronic health records and various biological sources. This research aims to bridge the gap between genetic information and its actual impact on health, making genetic testing results more practical for clinicians and patients.

Dr. Ernest Turro's lab focuses on understanding the genetic causes behind rare diseases using advanced genomic techniques. The lab specifically combines whole-genome sequencing with RNA sequencing of different blood cell types to enhance the diagnosis of rare disease patients. Through their work, they aim to uncover novel genetic variants that contribute to these diseases and improve precision medicine approaches.

Dr. Saghi Ghaffari's lab at the Icahn School of Medicine focuses on understanding how certain cellular organelles, like mitochondria and lysosomes, play critical roles in blood cell development and leukemia. They explore how these organelles influence the maturation of red blood cells and the behavior of leukemic stem cells. By uncovering these mechanisms, the lab aims to develop new therapeutic strategies for blood disorders and leukemia.